Merck’s KEYTRUDA (pembrolizumab) Approved in China...
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China as monoth...
June 22, 2020
10:50 am By Neha Mule